Should I buy Xylem Inc. (XYL) stock or is it too late?
⭐ The most reliable of them, either direction: Jefferies — 80% of its targets hit on this sector (293 calls tested). It aims for $150 (+46 %), call made on August 25, 2026, maturing on August 25, 2027 (50 d ago).
Firm-by-firm track record on Xylem Inc.
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| RBC Capital | 70 % | +14.7 % | 20 | $164 +60% |
| Barclays | 67 % | +9.1 % | 6 | $139 +36% |
| Stifel | 70 % | +9.1 % | 20 | $160 +56% |
| Baird | 57 % | +8.1 % | 7 | $165 +61% |
| Oppenheimer | 50 % | +8.0 % | 8 | $158 +54% |
| Citigroup | 60 % | +1.7 % | 5 | $148 +44% |
| BMO Capital | 100 % | +15.0 % | 6 | — |
| Morgan Stanley | 40 % | +5.7 % | 5 | — |
✅ Reasons to believe
- 78% of analysts rate it a buy (Buy consensus, 9 ratings) — a sign of market conviction.
- Median price target $154, i.e. +50% from the current price ($103).
- The most reliable firm on XYL, RBC Capital (70% hit rate, 20 scored calls), targets $164 (call made on July 29, 2026, maturing on July 29, 2027) (+60%) in its most recent call, and $176 (call made on October 29, 2025, maturing on October 29, 2026) (+72%) in the one coming due soonest.
- 5 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 9 ratings, 2 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
The analyst consensus on XYL
Median target $154 (+50%) · 9 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Xylem Inc. now?
We won't decide for you. The facts: 78% of analysts rate it a buy, median target $154 (+50%), and RBC Capital (most reliable on XYL, 70%) targets $164. Weigh that against valuation (P/E ~24). This is not personalized advice.
Is it too late to invest in Xylem Inc.?
Not according to analysts: the median target ($154) is still +50% above the current price ($103) (most reliable on XYL: RBC Capital, 70%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Xylem Inc. still worth investing in?
It depends on the gap between the price ($103) and its estimated value: analysts target $154 on median (+50%), with 78% buys (most reliable on XYL: RBC Capital, 70%). Cross-check with their real reliability on XYL and the cautions above. Information, not advice.
What's the main risk in buying XYL?
The consensus is not unanimous: of 9 ratings, 2 are neutral.
→ Go deeper: the full Xylem Inc. profile (consensus, analyst reliability, price target, performance).